CD63 and benign prostatic hyperplasia: S‐EVs captured using CD63 antibodies show a significant difference between AdvPCa versus LPCa patients in those that are also CD9+ (CD9+ CD63+; Figure 1c, ****P < 0.0001), but not significant between AdvPCa and BPH.